S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:PROK

ProKidney (PROK) Stock Price, News & Analysis

$1.64
+0.07 (+4.46%)
(As of 03/28/2024 ET)
Today's Range
$1.54
$1.65
50-Day Range
$1.20
$1.77
52-Week Range
$1.12
$13.51
Volume
466,004 shs
Average Volume
547,080 shs
Market Capitalization
$386.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

ProKidney MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
479.3% Upside
$9.50 Price Target
Short Interest
Bearish
29.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of ProKidney in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.65) to ($0.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.89 out of 5 stars

Medical Sector

841st out of 938 stocks

Biotechnology Industry

38th out of 47 stocks

PROK stock logo

About ProKidney Stock (NASDAQ:PROK)

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

PROK Stock Price History

PROK Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
ProKidney assumed with an Equal Weight at Morgan Stanley
PROK Mar 2024 7.500 call
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
ProKidney (NASDAQ: PROK)
BTIG Reaffirms Their Buy Rating on ProKidney (PROK)
PROK Jan 2024 10.000 call
ProKidney GAAP EPS of -$0.18
ProKidney Reports Third Quarter Financial Results
See More Headlines
Receive PROK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:PROK
Fax
N/A
Employees
163
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.50
High Stock Price Target
$16.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+479.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-35,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($42.77) per share

Miscellaneous

Free Float
129,513,000
Market Cap
$386.11 million
Optionable
Optionable
Beta
1.06
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Timothy A. Bertram D.V.M. (Age 69)
    Ph.D., Founder
    Comp: $970.4k
  • Mr. Todd C. Girolamo Esq. (Age 59)
    J.D., M.B.A., Chief Legal Officer & Corporate Secretary
    Comp: $600.17k
  • Dr. Bruce Culleton M.D.
    CEO & Director
  • Dr. Glenn Schulman M.P.H.
    Pharm. D., Pharm.D., Senior Vice President of Investor Relations
  • Ms. Mary Weger (Age 65)
    Chief People Officer
  • Dr. Joseph M. Stavas M.D.
    M.P.H., Senior VP and Head of Global Clinical Development & Interventional Procedures
  • Dr. Darin J. Weber Ph.D. (Age 56)
    Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access
  • Mr. Nikhil L. Pereira-Kamath
    Chief Business Officer
  • Mr. Richard Williams
    Senior Vice President of Information Technology
  • Dr. Aparna Sahoo M.D.
    VP & Head of Global Clinical Development

PROK Stock Analysis - Frequently Asked Questions

Should I buy or sell ProKidney stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProKidney in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PROK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PROK, but not buy additional shares or sell existing shares.
View PROK analyst ratings
or view top-rated stocks.

What is ProKidney's stock price target for 2024?

3 Wall Street analysts have issued 12 month price objectives for ProKidney's shares. Their PROK share price targets range from $3.00 to $16.00. On average, they expect the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 479.3% from the stock's current price.
View analysts price targets for PROK
or view top-rated stocks among Wall Street analysts.

How have PROK shares performed in 2024?

ProKidney's stock was trading at $1.78 at the beginning of the year. Since then, PROK shares have decreased by 7.9% and is now trading at $1.64.
View the best growth stocks for 2024 here
.

When is ProKidney's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PROK earnings forecast
.

How were ProKidney's earnings last quarter?

ProKidney Corp. (NASDAQ:PROK) posted its earnings results on Tuesday, November, 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.02.

What ETF holds ProKidney's stock?

ALPS Medical Breakthroughs ETF holds 177,981 shares of PROK stock, representing 1.93% of its portfolio.

Who are ProKidney's major shareholders?

ProKidney's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (1.23%), Vanguard Group Inc. (1.23%), Charles Schwab Investment Management Inc. (0.11%), Nuveen Asset Management LLC (0.06%), Federated Hermes Inc. (0.05%) and Barclays PLC (0.03%).
View institutional ownership trends
.

How do I buy shares of ProKidney?

Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PROK) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners